HopeStage
Back to all studies
TerminatedEUCTR 2012-005000-17

A randomized, double-blind, placebo-controlled, parallel-group proof of concept study to evaluate the effect of AFQ056 in OCD (OCD) patients resistant to Selective Seroton...

This historical record does not confirm current site availability.

Historical research recordMultiple countries
The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Who could participate?

This study is for people with OCD. Other eligibility criteria apply.

Listed locations
Bulgaria · Czechia and 2 more locations
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed
Recruitment status
Terminated
Enrollment listed in the registry
120
Sponsor
Novartis Pharma Services AG
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United Kingdom, Bulgaria, Czechia, ...
Age range
Not clearly listed
Official registry ID
EUCTR 2012-005000-17
Official title
Show the full official title

A randomized, double-blind, placebo-controlled, parallel-group proof of concept study to evaluate the effect of AFQ056 in obsessive compulsive disorder (OCD) patients resistant to Selective Seroton...

Recruitment & locations

Terminated

Bulgaria · Czechia · Germany

1 more locations
  • United Kingdom
Registry details
Historical country statuses

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Novartis Pharma Services AG, a pharmaceutical company.

Who can participate?

This study is for people with OCD. Other eligibility criteria apply.

Is this study still recruiting?

The historical registry lists this study as terminated.

Want to explore more studies?

Explore studies